Eli Lilly and Company $LLY Holdings Decreased by Fifth Third Bancorp

Fifth Third Bancorp lowered its position in Eli Lilly and Company (NYSE:LLY) by 0.6% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,739,872 shares of the company’s stock after selling 10,916 shares during the quarter. Eli Lilly and Company accounts for 3.3% of Fifth Third Bancorp’s holdings, making the stock its 5th largest position. Fifth Third Bancorp’s holdings in Eli Lilly and Company were worth $2,013,171,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Artemis Wealth Advisors LLC grew its position in shares of Eli Lilly and Company by 4.9% in the 3rd quarter. Artemis Wealth Advisors LLC now owns 467 shares of the company’s stock valued at $540,000 after buying an additional 22 shares during the last quarter. Endeavor Private Wealth Inc. increased its stake in shares of Eli Lilly and Company by 9.1% in the third quarter. Endeavor Private Wealth Inc. now owns 864 shares of the company’s stock valued at $999,000 after buying an additional 72 shares during the period. King Luther Capital Management Corp raised its position in shares of Eli Lilly and Company by 2.0% during the third quarter. King Luther Capital Management Corp now owns 212,351 shares of the company’s stock worth $245,707,000 after acquiring an additional 4,148 shares during the last quarter. Banyan Capital Management Inc. bought a new position in shares of Eli Lilly and Company during the third quarter worth about $868,000. Finally, Spectrum Planning & Advisory Services Inc. lifted its stake in shares of Eli Lilly and Company by 127.2% in the third quarter. Spectrum Planning & Advisory Services Inc. now owns 534 shares of the company’s stock worth $618,000 after acquiring an additional 299 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock opened at $1,437.46 on Thursday. The stock has a market capitalization of $1.35 trillion, a PE ratio of 46.66, a price-to-earnings-growth ratio of 1.72 and a beta of 0.40. The company’s 50-day moving average is $1,231.13 and its 200-day moving average is $1,106.42. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,453.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same period in the previous year, the company posted $7.02 EPS. The firm’s revenue was up 38.6% compared to the same quarter last year. Equities research analysts expect that Eli Lilly and Company will post 35.67 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.

Eli Lilly and Company News Summary

Investors following LLY have been watching these news items:

• Positive Sentiment: Lilly reported positive 52-week Phase 3b results for Taltz plus Zepbound in adults with psoriatic arthritis and obesity. Nearly three times as many combination-treatment patients achieved at least a 50% reduction in disease activity versus Taltz alone, potentially broadening Zepbound’s use and commercial opportunity. Article: Phase 3b Taltz and Zepbound results
• Positive Sentiment: A recent report says Lilly raised its 2026 sales outlook to as much as $92 billion, reinforcing expectations that strong demand for its obesity and diabetes medicines can drive continued growth. Article: Lilly’s 2026 sales outlook
• Negative Sentiment: The FDA is requiring GLP-1 drugmakers to add a warning about rare NAION-related vision loss. Zepbound is among the medicines affected, creating a potential safety concern for Lilly’s key product category. Article: FDA warning on GLP-1 drugs

Insider Buying and Selling

In other news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on LLY shares. BMO Capital Markets reiterated an “outperform” rating and issued a $1,650.00 target price on shares of Eli Lilly and Company in a report on Friday, October 30th. UBS Group raised their price target on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a “buy” rating in a report on Friday, October 30th. TD Cowen restated a “buy” rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. HSBC boosted their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. Finally, Jefferies Financial Group upped their price objective on shares of Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,416.64.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.